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SUMMARY – Metastatic tumors are the most common malignancy of bone. Many patients 
with spinal metastases present with pain and pathologic fractures. The advent of interventional radi-
ology resulted in alternative and less invasive treatment of these patients. This article presents mini-
mally invasive (percutaneous) procedures that are currently in use, i.e. vertebroplasty, kyphoplasty, 
osteoplasty, radiofrequency ablation, cryoablation, and transarterial embolization. Indications, con-
traindications, results and complications are also discussed. According to our current knowledge of 
the results reported in the literature, minimally invasive techniques are successful methods for the 
treatment of metastatic spinal and extraspinal disease and can be used as alternative treatment to 
standard surgical or non-surgical procedures.
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Introduction
Metastatic tumors are the most common malig-
nancy of bone, affecting 10%-30% of all cancer pa-
tients1. Vertebral column is the most common site 
of such metastases, spinal metastases being found in 
36% of patients who died from neo plastic disease2. 
Prostate, breast, lung, kidney, and thyroid cancers ac-
count for 80% of skeletal metas tases1,2. Due to medi-
cal advancement, there has been an increase in surviv-
al rates among cancer patients despite the increase in 
the incidence of metastatic lesions3. The predominant 
symptom in patients with spinal metastases is pain, 
which can be of three types: constant localized pain, 
radicular pain, and axial pain4. Traditional pain man-
agement techniques involve a combination of phar-
macotherapy, radiotherapy and surgical procedures4. 
Axial pain, most frequently associated with mechani-
cal instability of the spine or pathologic vertebral body 
fracture, is worsened by physical activity but relieved 
at rest5. Axial pain is generally treated by surgical sta-
bilization of the spine5. Recent technological advances 
combined with innovative interventional radiology 
techniques can now offer alternative, less invasive 
treatment options for many patients with malignant 
vertebral body infiltration5.
In this review, the authors will discuss minimally 
invasive procedures used in palliative treatment of spi-
nal and extraspinal metastases: vertebroplasty, kypho-
plasty, osteoplasty, radiofrequency ablation, cryoabla-
tion, and transarterial embolization.
Methods
Percutaneous vertebroplasty
The procedure involves percutaneous access to 
the vertebral body with a large (11 or 13 gauge) in-
troducer needle (cannula) and injection of the polym-
ethyl methacrylate (PMMA) cement in a semiviscous 
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state into the vertebral body. The safest needle path at 
thoracic and lumbar level is transpedicular approach6. 
The anterolateral approach avoiding injury of the ca-
rotid-jugular complex is typically followed at cervical 
levels3,6. The method was first described by Galibert 
et al., who performed percutaneous acrylic cement in-
jection for the treatment of aggressive vertebral body 
hemangioma7. The procedure that is usually carried 
out under local anesthesia combined with sedation is 
performed under fluoroscopic (x-ray) guidance. The 
procedure must be carried out in an operating theater 
or interventional radiology suite under strict aseptic 
conditions. Biplane fluoroscopy (double C-arm an-
giography unit) in interventional radiology suite offers 
continuous two-dimensional guidance that enables 
optimal control and the safest access to the vertebral 
body (Fig. 1). This procedure can also be carried out 
using computed tomography (CT) in combination 
with fluoroscopy; however, most centers reserve this 
technique for selected cases4.
Thoracic and lumbar procedures are performed 
with the patient in prone position. The level to be 
treated is marked under fluoroscopy. A clear view of 
the targeting pedicle (with the entire cortical circum-
ference) is mandatory before needle placement. The 
‘bull’s eye’ needle approach to the pedicle (perfect 
parallel alignment of the needle in tube direction, so 
the needle is seen as a spot) is simple and enables safe 
needle placement through the pedicle into the verte-
bral body. Transpedicular needle passage is a criti-
cal part of the procedure. Any error in the direction, 
e.g., crossing the medial pedicular wall, is potentially 
catastrophic, as entry into the spinal canal carries the 
risk of nerve root damage. Targeted needle position is 
achieved when the tip of the needle is in the ventral 
part of the vertebral body as close to the midline in 
coronal plane as possible (Fig. 2 a, b, c). Bone biopsy 
can be taken using coaxial technique through the same 
Fig. 1. Interventional radiology suite with double C-arm 
angiography unit that enables biplane fluoroscopy. The 
percutaneous vertebroplasty procedure with cement 
injection is shown.
Fig.  2. Percutaneous vertebroplasty of Th12 and L1 vertebral bodies in a patient with pathologic compression fractures 
with unipedicular approach under fluoroscopy control. Lateral projection on fluoroscopy shows the position of the needles 
in the ventral part of the vertebral bodies (a); cement distribution in lateral and anteroposterior projection on fluoroscopy 
shows no leakage outside the vertebral bodies after the procedure (b, c).
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needle before the cement is injected. The two needle 
(bipedicular) approach is used when the position of 
the needle is in the lateral part of the vertebral body 
and the cement is not distributed through the entire 
vertebral body (Fig. 3 a, b). The cement is injected 
manually under continuous fluoroscopic control. The 
filling pressure must be as low as possible while still 
generating cement passage through the needle. Using 
this type of technique, the procedure can be stopped 
if any cement leakage in venous plexus or outside the 
vertebral body is noticed.
The overall risk associated with percutaneous ver-
tebroplasty for malignant disease is ≤10%4,8,9. The most 
frequent complication is local cement leakage. A risk 
factor for such a complication is a bone defect of the 
posterior vertebral wall or pedicle wall breach10. Al-
though the majority of cement leakage are asymptom-
atic, severe neurological complication can result from 
leakage into the spinal canal11. There is also the risk of 
pulmonary embolism caused by the cement that has en-
tered the paravertebral venous plexus. The reported rate 
of pulmonary cement embolism is 3.4%12. Pulmonary 
embolism may be symptomatic or asymptomatic13,14. 
The occurrence of diffuse, extensive lung embolization 
is only possible when a considerable amount of cement 
is injected in a very low viscosity state14.
High viscosity cements have improved the unifor-
mity of cement filling and decreased the rate of leak-
age15. Vertebroplasty has been shown to be extremely 
effective in improving pain from vertebral fractures. 
Within the first 48 hours after the procedure, an an-
algesic effect is achieved that persists for at least 6 
months16. This effect is attributed to stabilization that 
results from preventing micromovements responsible 
for vertebral pain. Additional effect of vertebroplasty 
is destruction of nerve endings by the exothermic re-
action occurring during polymerization17. There is also 
a hypothesis that PMMA has an inherent tumoricidal 
or cytotoxic effect18.
The reported analgesic efficacy is 86% at 1 month, 
and 92% at 6 months12. In the past three years, these 
results have been challenged and have become a sub-
ject of scientific and clinical debate19. This is mostly 
due to the results of two randomized, double blind, 
placebo-controlled trials published by Buchbinder et 
al.20and Kallmes et al.21. Nevertheless, these reports 
have been challenged by other reports22,23, which are 
also concordant with our own results. However, there 
are significant differences in the risk taking, expecta-
tions, and perseverance in people who are willing to 
relegate their treatment to chance versus patients who 
refuse to participate24. In general, there has also been 
an increase in the use of other, complementary meth-
ods to threat chronic musculoskeletal pain worldwide 
but, with some exceptions, there is no solid enough 
scientific evidence to support the use of these methods 
in musculoskeletal conditions25. 
Vertebroplasty is indicated in painful vertebral 
body tumors. In cancer patients, the procedure is used 
particularly in symptomatic treatment of osteolytic 
bone metastases and myeloma producing severe axial 
(non-radiating) pain due to fractured vertebrae. As 
vertebroplasty is intended only to treat pain and con-
solidate the weight-bearing bone, other specific tumor 
therapy should be given in conjunction when appropri-
ate26. The method could be combined with radiation 
therapy (performed before or after vertebroplasty). 
The method can be even simultaneously performed 
Fig. 3. Percutaneous vertebroplasty 
of Th12 in a patient with metastatic 
renal cell carcinoma with bipedicular 
approach. The anteroposterior 
projection on fluoroscopy shows the 
position of the needles (a) that enabled 
distribution of the cement through the 
entire vertebral body (b). The patient 
presented with immediate and long-
term symptom relief.
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with radiotherapy27. Alternatively, CT image-guided 
procedure can be used as a platform technology for 
near-simultaneous spinal (and extraspinal) stereotac-
tic radiotherapy28.
Absolute contraindications for vertebroplasty are 
infection, uncorrectable coagulopathy, symptomatic 
spinal cord compression at the level of the fracture, 
severe cardiopulmonary disease, lack of surgical back 
up, or patient monitoring facilities. Relative contrain-
dications are inability of the patient to lie prone for the 
duration of the procedure, acute burst fractures, and 
complete loss of vertebral height (vertebra plana)29.
Kyphoplasty
Kyphoplasty was introduced in 2001. It is a modi-
fication of vertebroplasty employing a balloon tamp 
to restore vertebral height and create a cavity inside 
the vertebral body to accommodate the implanted ce-
ment30. The balloon tamp is advanced and inflated 
through a 9-11 gauge cannula inserted as in verte-
broplasty. The goal is to correct or prevent kyphotic 
deformities after loss of vertebral height. However, 
the fundamental principle of both vertebroplasty and 
kyphoplasty remains mechanical bone stabilization 
with cement injection31. 
The advantages of kyphoplasty are restoration of 
vertebral body height and correction of kyphosis32,33. 
The reported mean height restoration after kyphop-
lasty for compression fractures is around 3-5 mm at 
the center of the vertebral body34. 
In addition to providing rapid pain relief, balloon 
tamp kyphoplasty has the advantage of reducing acute 
fractures, allowing controlled cement placement un-
der lower pressure, and improving deformity, which is 
especially beneficial in elderly patients for restoration 
of overall spinal sagittal alignment and kyphotic de-
formity33. Additional advantage of kyphoplasty is less 
cement leakage compared to vertebroplasty33,35. 
Disadvantages of kyphoplasty as compared to ver-
tebroplasty are that kyphoplasty is always performed 
under general anesthesia, longer duration of the pro-
cedure, and the cost of the procedure is 10 to 20 times 
higher32,33. 
According to data in the literature available, both 
vertebroplasty and kyphoplasty procedures showed no 
significant difference in pain relief after 6 months36. 
The choice of the method for a particular clinical case, 
therefore, should be made with full knowledge of the 
advantages and shortcomings of both procedures.
Osteoplasty
Cementoplasty of the sacrum (sacroplasty) and ac-
etabulum (acetabuloplasty) and other weight-bearing 
bones (osteoplasty in general) are procedural variants 
of percutaneous vertebroplasty aiming to palliate pain 
by cement reinforcement of malignant osteolytic le-
sions32. Effective pain management of painful in-
sufficiency fractures or malignant osteolysis of the 
sacrum, the pubic rami, the ischial tuberosities and 
the acetabulum may be achieved with image guided 
injection of the cement31. The same principles apply 
for the extraspinal cementoplasty or osteoplasty as in 
percutaneous vertebroplasty. CT guidance is advo-
cated for acetabuloplasty, whereas the ‘bull’s eye’ fluo-
roscopic approach may be employed for pubic osteo-
plasty32 (Fig. 4). Injection of iodinated contrast before 
cementoplatsy is advocated to predict distribution of 
cement and visualize the potential pathways of ce-
ment extravasation32. The potential complications in-
clude cement-induced injury of sensitive neurovascu-
lar structures like the obturator and pudendal nerve37. 
Intra-articular cement leak into the hip joint has also 
Fig. 4. Osteoplasty in a patient with painful osteolytic metastases of the iliac 
bone. The puncture of the iliac bone was performed under computed tomography 
(CT) control and cement was injected under continuous fluoroscopy control in 
the same interventional suite unit. The image shows distribution of the cement 
on control CT.
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been described without any clinical significance37,38. 
Cementoplasty of osteolyses located in the diaphysis 
of long weight-bearing bones like femur should be 
avoided because of inadequate bone consolidation and 
pathologic fractures. However, femoral head lesions 
have been successfully treated38. The reported rates of 
pain relief after osteoplasty for extraspinal bone me-
tastases are comparable to those of vertebroplasty39.
Percutaneous radiofrequency ablation
Radiofrequency ablation (RFA) uses thermal ener-
gy to destroy tumor cells. In the musculoskeletal sys-
tem, the method was first used to treat painful oste oid 
osteomas, benign bone tumors40. The procedure starts 
with an introducer needle insertion into the vertebral 
body under fluoroscopic (or CT) guidance in the same 
way as described for percutaneous vertebroplasty. This 
procedure is also performed under local anesthesia 
combined with sedation. With the tip of the needle in 
the target position, the electrode is passed through the 
needle into the tumor (Fig. 5 a, b, c). The electrode is 
attached to a radiofrequency generator. 
The high-frequency alternating current from the 
electrode generates marked agitation of the ions in 
the tissue that surrounds the uninsulated tip of the 
probe. The frictional heat results in thermal coagula-
tion necrosis of the surrounding tissue4,41,42. Roughly, 
the size of ablation correlates with the intensity and 
duration of energy deposition40. The diameter of local 
coagulation necrosis is a function of the local mean 
temperature42,43. For effective heating throughout the 
tumor, it is necessary to achieve 60-100 °C and main-
tain it throughout the target volume for at least 4-6 
min41. The types of the electrodes are plain, expand-
able, and cooled electrodes. Plain electrodes are used 
for the treatment of small lesions (<5 mm), expandable 
electrodes create large, spherical shapes up to 7 cm, 
and cooled electrodes can achieve coagulation diam-
eter up to 3 cm42.
There is a risk of destroying non-target healthy 
tissue that surrounds the tumor. Therefore, thermal 
effects of radiofrequency heating on the adjacent soft 
and neural tissue must be considered before RFA is 
applied to spinal tumors44. A margin of safety is pro-
vided in cases in which preserved cancellous or corti-
cal bone is between the lesion and the spinal canal45. 
Electrodes with short active tip (length of 1 cm) pro-
vide additional safety with less damage to the sur-
rounding tissue46. 
About 80% of patients reported a decreased use of 
analgesics after RFA47. The method produces rapid, 
significant and enduring pain control in bone metas-
tases, still evident at one-year follow up in most cases, 
and elicits marked improvement in the quality of life 
of treated patients48. Theories for its mechanism of ac-
tion include destruction of sensory nerve fibers, re-
duction of lesion size, and destruction of tumor cells 
producing nerve-stimulating factors4. 
Fig. 5. Radiofrequency ablation of osteoid osteoma of the femur. The puncture pathway was determined under computed 
tomography control; the introducer needle was placed at the exact position of the tumor (white arrow) (a); radioablation 
probe was introduced through the introducer needle and placed into the nidus of the osteoid osteoma to perform ablation 
(white arrow) (b); available at: http://www.health-writings.com.
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The percutaneous RFA is indicated as co-adjuvant 
palliative treatment in patients with bone metasta-
ses and who do not benefit from standard therapy48. 
The method can be combined with percutaneous ver-
tebroplasty that provides stabilization of the treated 
segment5,44. There is also a positive effect of RFA on 
vertebroplasty. Data show that if RFA is carried out 
before vertebroplasty, the risk of cement extravasation 
is reduced49. The aim of performing radiofrequency 
heat ablation before vertebroplasty is to destroy tumor 
tissue and to thrombose the paravertebral and intra-
vertebral venous plexus, and thereby minimize the 
procedure-related complications43.
Contraindications to percutaneous RFA are the 
same as described for percutaneous vertebroplasty. Rel-
ative contraindication exists in patients with extensive 
osteolysis with no intact cortex between the tumor and 
the spinal cord or nerve roots because of the potential 
for thermal injury to the adjacent neural tissue45.
Cryoablation
Cryoablation has a long history of successful treat-
ment of neoplasms in several organs and has also 
recently emerged as an exceptional method for the 
treatment of metastatic disease involving bone and 
soft tissue outside the liver and lung50. The rationale 
for using cryoablation for this clinical need is based 
on its ability to treat often complex metastatic disease 
effectively, while preserving adjacent normal critical 
tissue51. Careful monitoring of the cryoablation mar-
gin is possible, due to the visibility of the ice ball on 
CT and magnetic resonance imaging (MRI), which is 
a key advantage of cryoablation over the other meth-
ods51,52.
Cryoablation devices include percutaneous cryo-
probes that deliver room temperature argon gas 
through a sealed, segmentally insulated probe. Rapid 
expansion of the gas in the sealed distal cryoprobe re-
sults in rapid cooling, reaching -100 °C at the probe 
tip within a few seconds. Small diameter probes (1.2-
2.4 mm) allow percutaneous use of these devices51. 
Multiple cryoprobes may be placed in geometric con-
figuration that provides best coverage of the tumor 
with particular attention being paid to the treatment 
of the bone-tumor interface while avoiding adjacent 
critical structures. In general, the probes are placed 2 
cm apart within the tumor and 1 cm from the outer 
tumor margin. A single freeze-thaw-freeze cycle is 
performed for each lesion, with a goal treatment time 
of 10-15 min50. To avoid uncertain cell death with 
temperatures between 0 and -20 °C, repeated freeze-
thaw-freeze cycles are needed. Indeed, ice crystals are 
mainly extracellular during the first freezing phase; 
during thawing phase, water diffuses into the intrac-
ellular compartment due to osmotic gradients, and the 
second freezing phase achieves intracellular ice crys-
tals, leading to membrane rupture and cell death53. 
The longer the duration of the thawing phase, the 
greater is the cell damage it causes53. Repetition of the 
treatment cycle is associated with more extensive and 
more certain tissue destruction54. Monitoring may be 
performed as frequently as every 2 min with limited 
non-contrast CT, although the ablation zone may 
also be seen on MRI50,52. The ablation zone is identi-
fied as a well-margined low attenuation region along 
the distal shaft of the cryoprobe51. The outer edge of 
the ice, as seen on the body window at level settings 
(W400, L40) corresponds to 0 °C, with cell death re-
liably occurring 3 mm deep near the edge. For cura-
tive cryoablation, the margins of the ice ball should 
extend 3 to 5 mm beyond the tumor margins53. The 
probes may be actively used until they reach approxi-
mately 25 °C, at which point they can be removed51. 
Recent studies report on the interest in cryoablation 
for palliative treatment of bone metastases, with very 
promising results and few complications51,55.
Cryoablation is indicated in painful bone and soft 
tissue metastasis. The pain should be described by pa-
tients as at least moderate or severe and localized in one 
or two locations; patients with diffuse skeletal metasta-
ses are better served with systemic therapies51. Lesions 
should be osteolytic, mixed osteolytic-osteoblastic, or 
primary soft tissue component. Osteoblastic metastases 
require bone drill51. The required margin of safety be-
tween target lesion and vital structures depends on the 
ability to visualize adjacent critical structures, the use 
of technique to displace normal tissue, the use of ther-
mal protection and monitoring devices, and experience 
of the interventional radiologist51.
The major advantage of cryoplasty is the possibil-
ity of precise monitoring of the treatment zone, which 
allows complete treatment of the lesion and preserva-
tion of the adjacent structures. It also allows the use 
of multiple cryoprobes simultaneously, thus enabling 
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generation of large ice balls (>8 cm) and the ability 
to shape the ablation zone according to the tumor. 
Cryoablation allows the additional option of tissue 
displacement with catheter guided balloons, which is 
not possible with heat-based methods due to thermal 
limitation of these devices.
The major disadvantage of cryoablation is that it 
is more time consuming compared to RFA (average 
procedure lasts for about 2 hours) and it may be more 
costly than RFA (the cost varies greatly depending on 
the size of the tumor).
The results of cryoablation treatment that are known 
so far are promising. On the Cleeland brief pain inven-
tory56, the mean score for worst pain decreased signifi-
cantly in 43% of patients in 4 weeks, which is consid-
ered clinically significant57. At 4 weeks of cryoablation, 
patient reported pain relief ranged from 50% to 100%, 
which compared favorably to RFA51.
Percutaneous transarterial embolization
The procedure involves percutaneous selective 
transarterial deliverance of the embolization agent 
for direct devascularization of a hypervascular tumor. 
Transarterial embolization of spinal tumors was de-
scribed in 1974 by Benati, who published first results 
of transfemoral selective embolization in the treat-
ment of cranial and vertebro-spinal vascular malfor-
mations and tumors58.
Selective catheterization of tumor’s feeding artery/
arteries is performed through the femoral artery ac-
cess. The procedure that can be carried out under lo-
cal anesthesia combined with sedation is performed 
under fluoroscopic guidance in an interventional ra-
diology suite. The iodine contrast agent administered 
intra-arterially is visualized by fluoroscopy of the an-
giographic unit (C-arm). Digital subtraction angiog-
raphy (DSA) is a method that enables subtraction of 
arteries from background tissue. With the DSA tech-
nique, the supraselective catheterization of arteries 
that feed the tumor is possible using special micro-
catheters (with outer diameter up to 0.4 millimeters). 
With the tip of the microcatheter in the target posi-
tion, the embolization material can be delivered to the 
tumor (Fig. 6 a, b). 
Various embolic materials are available for tran-
sarterial embolization. They can be in solid state like 
Fig. 6. Percutaneous transarterial embolization in a patient with multiple myeloma. The patient had already undergone 
surgical stabilization of the spinal column due to multiple pathologic fractures. However, because of the disease progression, 
another surgical stabilization was needed. The procedure was combined with preoperative percutaneous transarterial 
embolization. Supraselective catheterization of the artery that supplied the highly vascular tumor of the Th2 vertebra 
as shown with digital subtraction angiography (a) enabled efficient preoperative embolization with polyvinyl alcohol 
particles and microcoils. Complete devascularization of the tumor is seen (b); there was significant reduction of blood loss 
during the surgery (with permission of D. Lovric).
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particles (e.g., gelatin sponge, polyvinyl alcohol par-
ticles (PVA)) or coils, and in liquid state (alcohol, n-
butyl cyanoacrylate (NCBA), ethylene-vinyl alcohol 
copolymer (Onyx)). Embolization with PVA particles 
is the most commonly used method. Gelatin sponge 
and coils or a combination are also used in the setting 
of potential collaterals necessitating flow diversion59.
Spinal tumor embolization carries certain risks, 
including complications of vascular access (e.g., he-
matoma or pseudoaneurysm), radiation exposure, 
iodinated contrast, catheter manipulation (e.g., vessel 
dissection or rupture), or embolization (e.g., spinal or 
cerebral infarction)45. Embolization of vertebral body 
tumors is potentially dangerous because of numerous 
vascular channels around the vertebral column. Non-
target embolization can lead to catastrophic conse-
quences. Intraprocedural angiographic visualization 
of collaterals and Adamkiewicz’s artery is crucial. 
Occlusion of this artery can result in permanent neu-
rologic deficit or even paraplegia. 
The reported success rate of embolization is 37% 
(complete embolization of tumor) to 63% (partial em-
bolization)60. 
The main indication for transarterial embolization 
in metastatic spinal disease is preoperative emboliza-
tion. It represents a safe and effective procedure to de-
crease intraoperative blood loss59,60. It can also be used 
as a palliative therapeutic option that may offer rapid 
relief of symptoms61.
There is only one absolute contraindication to 
embolization in spinal region. Visualization of any 
dangerous anastomoses is an absolute contraindica-
tion. Uncorrectable coagulopathy is the major relative 
contraindication. Other relative contraindications are 
renal insufficiency and allergy to iodinated contrast 
media.
Minimally invasive (percutaneous) treatment of 
metastatic spinal and extraspinal disease at University 
Medical Centre Ljubljana, Slovenia
Percutaneous vertebroplasty for malignant disease 
was started by the authors at the Clinical Institute of 
Radiology in the year 2011. As a method of choice, it 
has been used in all 21 cases of pathological and os-
teoporotic fractures (11 thoracic and 10 lumbar) dur-
ing the last two years. The mean age of 13 patients 
(10 women and 3 men) was 68.2 (range 57-83) years. 
However, the majority of oncology patients treated at 
our department (8/13, 61%) presented with insuffi-
ciency fractures, as a consequence of osteoporosis and 
also long-term medicamentous treatment (e.g., cor-
ticosteroid therapy). Metastatic renal cell carcinoma 
was the most frequent cause of pathologic (osteolytic) 
fractures in our patients. Pre-procedural MRI was 
used in all patients in order to confirm bone mar-
row edema as a sign of a fresh fracture. Percutaneous 
bone biopsy was used in three (23%) patients dur-
ing vertebroplasty procedure. Among these patients, 
pathologic fractures were confirmed in two (66%) 
cases. Multiple level procedures were performed in 
five (38%) patients, two-level procedures in three pa-
tients, and three- and four-level procedures in one pa-
tient each. We achieved good cement distribution in 
vertebral body in all treated patients. No procedure 
related clinically important side effects were noticed 
(no leakage toward spinal canal or into intervertebral 
disks, and also no other inter-procedural complication 
or adverse reaction). Dramatic, immediate pain relief 
was achieved in the vast majority of cases. Immediate 
post-procedural significant pain relief was defined as 
reduction of pre-procedural visual analog scale (VAS) 
score, and was achieved in all our patients. Stabiliza-
tion of fracture (preventing additional collapse) and 
analgesic effect was achieved in the majority of patients 
(11/13, 85%). However, fracture of adjacent vertebral 
body occurred in two (2/13, 15%) patients within two 
months of the procedure. While one of these patients 
was treated conservatively, additional vertebroplasty 
was performed in the other case. Therefore, our initial 
experience confirmed the effectiveness and safety of 
the procedure in oncologic patients.
Although the fact that percutaneous RFA has 
been performed at the Clinical Institute of Radiology, 
it is not yet routinely used for skeletal lesions. Our 
experiences with skeletal RFA are therefore limited. 
However, with the introduction of cryoablation, both 
thermoablation techniques will gain an important role 
in selected patients.
Percutaneous transarterial embolization has been 
routinely used in our institution for many years. Em-
bolization of metastatic spinal and extraspinal disease 
has been most frequently used as preoperative proce-
dure to reduce major blood loss during the operative 
procedure. Also, the method has been successfully 
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used in some benign skeletal tumors (e.g., aneurysmal 
bone cyst).
The major advantage of performing minimally 
invasive (percutaneous) treatment by interventional 
radiologists is a diagnostic imaging support by their 
own department. Namely, different imaging modali-
ties (fluoroscopy, CT, MRI) can serve not only for 
pre- and post-procedural assessment, but also as an 
image guided tool. 
Conclusion
Vertebroplasty and its modifications (kyphoplasty 
and extraspinal cementoplasty) as well as thermal ab-
lation techniques (RFA and cryoablation) and transar-
terial embolization are successful minimally invasive 
methods for the treatment of metastatic spinal and 
extraspinal disease. The methods can be utilized as an 
additional or palliative treatment in selected patients. 
A combination of these methods as well as a combi-
nation with other surgical and nonsurgical treatments 
can be used. 
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Sažetak
MINIMALNO INVAZIVNO (PERKUTANO) LIJEČENJE METASTATSKE SPINALNE I 
EKSTRASPINALNE BOLESTI – PREGLEDNI ČLANAK
V. Salapura i M. Jeromel
Metastatski tumori su najčešća zloćudna bolest kostiju. Mnogi bolesnici s metastazama kralježnice dolaze s bolovima 
i patološkim prijelomima. Razvoj intervencijske radiologije omogućio je alternativno i manje invazivno liječenje ovih 
bolesnika. U članku se prikazuju minimalno invazivni (perkutani) zahvati koji se danas primjenjuju: vertebroplastika, 
kifoplastika, osteoplastika, radiofrekvencijska ablacija, krioablacija i transarterijska embolizacija. Potom se raspravlja o 
indikacijama, kontraindikacijama, rezultatima i komplikacijama ovih postupaka. Prema našim saznanjima iz literaturnih 
podataka, minimalno invazivne tehnike su uspješne u liječenju metastatske spinalne i ekstraspinalne bolesti te se mogu 
rabiti kao alternativa standardnim kirurškim i ne-kirurškim zahvatima.
Ključne riječi: Koštani tumori, metastaze; Kralježnica, tumori – metastaze; Vertebroplastika – metode; Kifoplastika; Ablacij-
ske tehnike; Kriokirurgija; Transarterijska kemoembolizacija; Palijativna skrb
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